Deferasirox

Generic Name: Deferasirox

Brand Names: Exjade, Jadenu, 恩瑞格, Deferasirox Accord, Deferasirox Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₅N_₃O_₄

CAS Number: 201530-41-8

Unique Ingredient Identifier: V8G4MOF2V9

Background: Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.

Indication: For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

Associated Conditions: Chronic Iron Overload

Associated Therapies: -

Clinical Trials

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

Phase 2

Completed

Conditions: Transfusional Iron Overload

Interventions: Drug: Deferasirox

First Posted Date: 2006-09-22

Last Posted Date: 2015-03-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 66

Registration Number: NCT00379483

Locations: 🇮🇹
Novartis Investigative Site, Torino, Italy

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

Phase 2

Completed

Conditions: Anemia
Hemosiderosis

Interventions: Drug: Deferasirox

First Posted Date: 2006-03-16

Last Posted Date: 2011-05-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 184

Registration Number: NCT00303329

Locations: 🇺🇸
Childres's Hospital Boston, Boston, Massachusetts, United States
🇺🇸
Stanford Hospital, Stanford, California, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 3 locations

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

Phase 3

Completed

Conditions: Diamond Blackfan Anemia
Thalassemia
Sickle Cell Disease
Myelofibrosis

Interventions: Drug: Deferasirox

First Posted Date: 2005-10-10

Last Posted Date: 2011-06-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1683

Registration Number: NCT00235391

Locations: 🇮🇹
Azienda Ospedali Vittorio Emanuele, Ferrarotto e San Bambino, Catania, Italy
🇮🇹
PresidioOspedaliero S. Luigi Curro, Catania, Italy
🇺🇸
PCTI, Columbus, Ohio, United States

and more 135 locations

A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

Phase 3

Completed

Conditions: Hemosiderosis
Beta-Thalassemia

Interventions: Drug: deferasirox

First Posted Date: 2005-09-15

Last Posted Date: 2017-03-01

Lead Sponsor: Novartis

Target Recruit Count: 252

Registration Number: NCT00171171

Locations: 🇸🇾
Novartis Investigative Site, Damascus, Syrian Arab Republic
🇱🇧
Ali Taher, Beirut, Lebanon

A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload

Phase 3

Completed

Conditions: Transfusion-dependent Iron Overload

Interventions: Drug: Deferasirox

First Posted Date: 2005-09-15

Last Posted Date: 2020-02-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1784

Registration Number: NCT00171821

Locations: 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)

Phase 4

Completed

Conditions: Beta-thalassemia Major
Hemosiderosis
Iron Overload
Rare Anemia

Interventions: Drug: Deferasirox

First Posted Date: 2005-09-15

Last Posted Date: 2011-08-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 233

Registration Number: NCT00171301

Locations: 🇸🇾
Novartis Investigative Site, Damascus, Syrian Arab Republic

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

Phase 3

Completed

Conditions: Transfusional Iron Overload in β-thalassemia

Interventions: Drug: Deferasirox

First Posted Date: 2005-09-15

Last Posted Date: 2011-05-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 506

Registration Number: NCT00171210

Locations: 🇺🇸
Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇬🇧
Novartis Investigative Site, London, United Kingdom

and more 4 locations

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Phase 4

Completed

Conditions: Iron Overload
Myelodysplastic Syndromes

Interventions: Drug: Deferasirox

First Posted Date: 2005-07-07

Last Posted Date: 2021-06-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT00117507

Locations: 🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Phase 2

Completed

Conditions: Iron Overload
Myelodysplastic Syndrome

Interventions: Drug: Deferasirox

First Posted Date: 2005-05-05

Last Posted Date: 2021-08-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 176

Registration Number: NCT00110266

Locations: 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸
Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, California, United States

and more 33 locations

Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias

Phase 2

Completed

Conditions: Beta-thalassemia
Myelodysplastic Syndromes
Fanconi Syndrome
Anemia, Aplastic
Anemia, Diamond-Blackfan

First Posted Date: 2003-06-04

Last Posted Date: 2017-08-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 175

Registration Number: NCT00061763

Locations: 🇺🇸
Stanford Hospital, Stanford, California, United States
🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy